{
  "retracted": false,
  "timestamp": 1541635200000,
  "updates": [
    {
      "timestamp": 1585049666359,
      "identifier": {
        "doi": "10.1007/s10096-018-3410-8"
      },
      "type": "correction"
    }
  ],
  "identifier": {
    "doi": "10.1007/s10096-018-3344-1"
  },
  "publisher": "Springer Science and Business Media LLC",
  "title": "Correction to: Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE)"
}
